Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VXA-CoV2-3.1
- Development stage
- Unknown
- Lead developer
- Vaxart
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
VXA-CoV2-3.1 is an investigational oral tablet vaccine developed by Vaxart for the prevention of symptomatic COVID-19. It utilizes a non-replicating adenovirus type 5 (Ad5) vector platform to deliver the gene for the SARS-CoV-2 spike protein, specifically targeting the XBB.1.5 variant. The vaccine is unique for its oral administration and thermostability, designed to induce both systemic and mucosal immunity (IgA) in the gut and respiratory tract. It incorporates a double-stranded RNA (dsRNA) adjuvant to enhance the immune response. VXA-CoV2-3.1 has been evaluated in a Phase 2b clinical trial (NCT06672055) supported by the U.S. government's BARDA Project NextGen, comparing its efficacy and safety against approved mRNA injectable boosters.
- Brand names
- VXA-CoV2-3.1 COVID-19 VaccineVXA-CoV-2-3.1 COVID-19 VaccineVXA-CoV 2-3.1 COVID-19 Vaccine
- Other names
- Vaxart oral COVID-19 vaccine (XBB.1.5)
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on VXA-CoV2-3.1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VXA-CoV2-3.1.